Janusz Jaworski - Concepedia

Author

Janusz Jaworski

Celltrion (South Korea)ORCID

Also Known As

Ewa Sawosz, J JAWORSKI, J Jaworski, J M Jaworski, J. Jaworski, Janusz Jaworski, Janusz Marek Jaworski, M Marasek

114

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Celltrion (South Korea)University School of Physical Education in Kraków Wroclaw Medical University Hanyang University Seoul Hospital Medical University of Białystok

About

Janusz Jaworski is an author at Celltrion (South Korea) specializing in kinesiology, rehabilitation, and exercise physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	5	5	84
2	Applied Physiology	5	5	84
3	Engineering	2	2	53
4	Education	1	1	10
5	Social Sciences	1	1	10

Janusz Jaworski

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study Dae‐Hyun Yoo, Nenad Prodanović, Janusz Jaworski, Annals of the Rheumatic Diseases	2016	278
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, Annals of the Rheumatic Diseases	2016	275
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study Won Park, Dae‐Hyun Yoo, Janusz Jaworski, Arthritis Research & Therapy	2016	137
Phase <scp>III</scp> Randomized Study of <scp>SB</scp>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis Michael E. Weinblatt, Asta Baranauskaitė, Jaroslaw Niebrzydowski, Arthritis & Rheumatology	2017	130
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Michael E. Weinblatt, Asta Baranauskaitė, Eva Dokoupilová, Arthritis & Rheumatology	2018	115
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial René Westhovens, Piotr Wiland, Marek Zawadzki, Lara D. Veeken	2020	54
Neural network for predicting the performance of credit card accounts Ilona Jagielska, Janusz Jaworski Computational Economics EngineeringMachine LearningData SciencePattern RecognitionPredictive Analytics	1996	42
The Effects of Intermittent Hypoxic Training on Anaerobic and Aerobic Power in Boxers Tadeusz Ambroży, Marcin Maciejczyk, A Klimek, International Journal of Environmental Research and Public Health	2020	37
The effect of methylprednisolone on proliferation of PBMCs obtained from steroid‐sensitive and steroid‐resistant rheumatoid arthritis patients Paula Śliwińska-Stańczyk, J Pazdur, Janusz Jaworski, Scandinavian Journal of Rheumatology	2007	34
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study Janusz Jaworski, Marco Matucci‐Cerinic, Hendrik Schulze‐Koops, Arthritis Research & Therapy	2019	32

Page 1